Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.64 |
| ▸ | RAB9A | P51151 | 6/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | KDR | P35968 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | TYK2 | P29597 | 2/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | MITF | O75030 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29581099 | 1.00 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL30210285 | 0.93 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL231897 | 0.89 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL29184186 | 0.87 | KDR (0.76) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL28947571 | 0.84 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL5898991 | 0.82 | GRM4 (0.60) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL10415452 | 0.82 | GRM4 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL6037590 | 0.82 | KDR (0.78) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL20990144 | 0.82 | NPC1 (0.67) | NPC1RAB9ASMN1; SMN2GRM4PKM | |
| SCHEMBL6037587 | 0.82 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2GRM4PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426682-B1 | COMBINATION OF A CXCR4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR | PROXIMAGEN LLC (US) | 2023-06-07 | — | — | EP | claimed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2025-10-16 | — | — | US | disclosed |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | PMV PHARMACEUTICALS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | PMV PHARMACEUTICALS, INC. | 2024-08-15 | — | — | US | disclosed |
| US-11938124-B2 | Combination therapy for treatment of cancer | PMV PHARMACEUTICALS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| CN-116710090-A | Heteroaryl amide inhibitors of CD38 | NAPA医疗有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-4225310-A1 | HETEROARYL AMIDE INHIBITORS OF CD38 | Napa Therapeutics Ltd. (VG) | 2023-08-16 | — | — | EP | disclosed |
| EP-3617196-B1 | N-(4-PYRIDYL) NICOTINAMIDE COMPOUND OR SALT THEREOF | ISHIHARA SANGYO KAISHA (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-110520130-A | USL-311 for treating cancer | PROXIMAGEN GROUP LTD | 2019-11-29 | — | — | CN | disclosed |
| US-20180273564-A1 | CARBON MONOXIDE RELEASING MOLECULES | AUCKLAND UNISERVICES LIMITED (NZ) | 2018-09-27 | — | — | US | disclosed |
| CN-107438437-A | Novel treatment for cancer | 普罗克斯马根有限公司 | 2017-12-05 | — | — | CN | disclosed |
| US-9808447-B2 | Inhibitors of Rho associated protein kinases (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170049760-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2017-02-23 | — | — | US | disclosed |
| US-9409868-B2 | Inhibitors of rho associated protein kinases (ROCK) and methods of use | H. Lee Moffin Cancer Center and Research Institute, Inc. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20140336440-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2014-11-13 | — | — | US | disclosed |
| EP-2627649-A1 | CXCR4 RECEPTOR ANTAGONISTS | Proximagen Limited (GB) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013112722-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-08-01 | — | — | WO | disclosed |
| WO-2012049277-A1 | CXCR4 RECEPTOR ANTAGONISTS | PROXIMAGEN LTD (GB) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140336440-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | NPC1 3255/4885RAB9A 502/4885SMN1; SMN2 3711/4885 |
| US-11938124-B2 | Combination therapy for treatment of cancer | TP53, KRAS, TP53BP1 | NPC1 3401/4885RAB9A 2955/4885SMN1; SMN2 3848/4885 |
| US-20250319063-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | TP53, TP53BP1, KRAS | NPC1 2254/4885RAB9A 2434/4885SMN1; SMN2 3942/4885 |
| US-20180273564-A1 | CARBON MONOXIDE RELEASING MOLECULES | MB, HMOX1, HMOX2 | NPC1 1698/4885RAB9A 2322/4885SMN1; SMN2 351/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | NPC1 3278/4885RAB9A 284/4885SMN1; SMN2 3167/4885 |
| US-20170049760-A1 | INHIBITORS OF RHO ASSOCIATED PROTEIN KINASES (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | NPC1 3255/4885RAB9A 502/4885SMN1; SMN2 3711/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | NPC1 2874/4885RAB9A 1423/4885SMN1; SMN2 4175/4885 |
| US-20240269126-A1 | COMBINATION THERAPY FOR TREATMENT OF CANCER | TP53, KRAS, TP53BP1 | NPC1 3401/4885RAB9A 2955/4885SMN1; SMN2 3848/4885 |
| US-12419880-B2 | Companion diagnostic tool for mutant p53 reactivating compounds | TP53, TP53BP1, KRAS | NPC1 3688/4885RAB9A 809/4885SMN1; SMN2 3967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.